Redeemable Noncontrolling Interest

12 Months Ended

Dec. 31, 2021

Noncontrolling Interest [Abstract]

Redeemable Noncontrolling Interest

Note 13: Redeemable Noncontrolling Interest

The Company is subject to the Exchange Agreement with respect to the vTv Units representing the outstanding 25.6% noncontrolling interest in vTv LLC (see Note 1).  The Exchange Agreement requires the surrender of an equal number of vTv Units and Class B Common Stock for (i) shares of Class A Common Stock on a one-for-one basis or (ii) cash (based on the fair market value of the Class A Common Stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications.  The exchange value is determined based on a 20 day volume weighted average price of the Class A Common Stock as defined in the Exchange Agreement, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications.

The redeemable noncontrolling interest is recognized at the higher of (1) its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date.  At December 31, 2021, and 2020, the redeemable noncontrolling interest was recorded based on the redemption value as of the balance sheet date of $25.0 million and $83.9 million, respectively.

Changes in the Company’s ownership interest in vTv LLC while the Company retains its controlling interest in vTv LLC are accounted for as equity transactions, and the Company is required to adjust noncontrolling interest and equity for such changes.  The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:

	December 31,
	2021			2020			2019
Net loss attributable to vTv Therapeutics Inc.    common shareholders	$	(12,987	)	$	(8,499	)	$	(17,913	)
Increase in vTv Therapeutics Inc. accumulated    deficit for purchase of LLC Units as a result    of common stock issuances		(5,084	)		(8,943	)		(17,971	)
Change from net loss attributable to    vTv Therapeutics Inc. common shareholders    and transfers to noncontrolling interest	$	(18,071	)	$	(17,442	)	$	(35,884	)